GSK plc (GLAXF)
Healthcare · PNK
Price as at 1 Oct 2026, 20:16 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
GSK plc trades at $23.25, which is 43% above the $13.34 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 78 out of 100, which is a wide moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 15.9 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
GLAXF dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.472 | 2 |
| 2025 | $0.630 | 3 |
| 2024 | $0.775 | 4 |
| 2023 | $0.693 | 4 |
| 2022 | $0.965 | 4 |
| 2021 | $1.38 | 4 |
| 2020 | $1.28 | 4 |
| 2019 | $1.27 | 4 |
| 2018 | $1.03 | 3 |
| 2017 | $1.29 | 4 |
| 2016 | $1.80 | 4 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
GLAXF earnings and analyst estimates
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
GLAXF passes 5 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
GLAXF peers
The largest companies in the same industry (Drug Manufacturers - General), then in the same sector.
- LLY Eli Lilly and Company
- JNJ Johnson & Johnson
- ABBV AbbVie Inc.
- MRK Merck & Co., Inc.
- NVSEF Novartis AG
- AZN.L AstraZeneca PLC
- NVO Novo Nordisk A/S
- PFE Pfizer Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is GSK plc (GLAXF) undervalued?
Against our fair value estimate of $13.34, GLAXF at $23.25 is 43% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
What is GLAXF's P/E ratio?
GLAXF trades at 15.9 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does GSK plc (GLAXF) pay a dividend?
Yes. GSK plc yields 3.61% at the current share price. It has paid $0.472 per share over the trailing twelve months. It has paid a dividend in each of the last 12 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
When does GLAXF report earnings next?
GSK plc is scheduled to report on 28 Oct 2026. Companies move earnings dates, so read it as scheduled rather than certain.
Where does SteadyShares get its GLAXF data?
Fundamentals for GLAXF come from company filings and exchange data, as listed on PNK; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 20:16 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for GLAXF, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.